Navigation Links
Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone
Date:1/6/2014

ng the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, development progress of the Company's companion diagnostics, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates or companion diagnostics and other factors discussed in the "Risk Factors" section of the Company's 10-Q filed with the Securities and Exchange Commission on October 23, 2013. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Epizyme, Inc. to Be Added to NASDAQ Biotechnology Index (NBI) and NASDAQ Global Select Market
2. Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
3. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
4. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
5. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
6. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
7. Advanced Biofuels USA's Joanne Ivancic Recognized as One of Top 100 People in the BioEconomy by Biofuels Digest
8. Westchase Neck Injury Chiropractor is Now Offering the Newest Advanced Care Treatments for Injury and Chronic Pain, Courtesy of Elan Wellness Center
9. ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
10. New Ocean Sensing and Monitoring Brings Tutorial Approach to Latest Advances
11. Phoenix Research Labs Partners with Voxeleron to Advance Technology for Eye Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat Pharma, ... 2 study evaluating the investigational oral NK-1 receptor ... with severe, chronic itch who are unresponsive or ... including topical steroids and antihistamines. ... Visual Analog Scale (VAS) itch score from baseline, ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult ... wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a ... Office of the Chief Scientist (OCS).  This ... receipt of grant support from the Office of the ...
(Date:12/15/2014)... 15, 2014  Origin Agritech Limited (NASDAQ GS: SEED) (" ... of crop seeds in China , today ... year 2014 ended September 30, 2014, before the market opens ... host a teleconference on January 8, 2015, at 8:00 a.m. ... to discuss the results. To participate in the call, please ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... PARIS, March 25 Hello, , ... and 2009 outlook has,been webcasted. The presentation is available ... http://www.thomson-webcast.net/uk/dispatching/?event_id=2ef87b3007af7a71 , a2e0f120f7f05e9c&portal_id=55a3fb63ef049550bc3b4d09baf7bf5e , ... it may be necessary to copy and paste,this hyperlink ...
... privately held biotechnology company focused on developing novel cancer ... viral vector, today announced that Frank Stonebanks, President and ... Venture Conference in Boston on Wednesday, April 1, 2009 ... , Cynvec, a privately held biotechnology company, is ...
... BMRN ) today announced that Jean-Jacques Bienaime, Chief ... the 4th Annual Citi Biotech Day in New York City ... may access a live audio webcast of the conference call ... . A replay of the call will be archived ...
Cached Biology Technology:BioMarin to Present at the 4th Annual Citi Biotech Day 2
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug Association ... regulatory agencies will speak and at least seven more will ... at the Omni Shoreham Hotel in Washington D.C. ... again to have significant support from the regulatory agencies in ... Europe in our effort to help advance the ...
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... firm, is pleased to announce the promotion of ... Director of Digital Forensics. In Schiff,s new role as ... the team of digital forensics examiners and provide leadership ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... It,s a project 500 million years in the making. Only ... Jurassic Park, it,s happening in a lab at the Georgia ... Georgia Tech researchers have resurrected a 500-million-year-old gene from bacteria ... coli ) bacteria. This bacterium has now been growing for ...
... of researchers from Greece and Spain have managed to ... to their application in biotechnology, by using strawberry tree ... and very fast. Strawberry tree leaf ( Arbutus ... two ingredients scientists can now produce silver nanoparticles, a ...
... step,ATP splitting in membrane protein dynamically measured for the ... Biological Chemistry How a transport protein obtains ... has been tracked dynamically by RUB researchers. Using time-resolved ... bacterial membrane protein MsbA and its interaction partner ATP. ...
Cached Biology News:Giving ancient life another chance to evolve 2Silver nanoparticle synthesis using strawberry tree leaf 2ATP splitting in membrane protein dynamically measured for the first time 2
Miniature FRENCH Pressure Cell with 3.7ml capacity; pressure up to 20,000 psi....
... CryoMed Freezers for IVF are designed for ... control, ease of setup and operation, and ... status are continuously displayed on the control ... data are printed by way of the ...
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
... Reverse Transcriptase is a recombinant Moloney ... MultiScribe Reverse Transcriptase is similar to ... its recommended usage. MuLV reverse transcriptase ... that uses single-stranded RNA as a ...
Biology Products: